← All trials
NCT01905592
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2013
- Primary completion
- Sep 1, 2017
- Completion date
- Feb 1, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 306
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- TesaroLead sponsor
- Myrexis Inc.Collaborator
- European Organisation for Research and Treatment of CancerCollaborator
- European Organisation for Research and Treatment of CancerOverall official - principal investigator
- Facing Our Risk of Cancer EmpoweredCollaborator
- SCRI Development InnovationsCollaborator
- US OncologyCollaborator
- Universidad Autonoma de BarcelonaStudy chair
- University of MilanStudy chair
- University of MilanCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.